AstraZeneca (LSE:AZN) sticks to mid- to high-single-digit 2026 revenue and low-double-digit core EPS guidance while facing FDA review delays for Etcamah and strong DESTINY-Breast09 data for Enhertu, ahead of Q2 results and a royalty deal on cliramitug that could pay up to $425M.
Previous Week Recap
- AZN 2026 Guidance Growth Doubts: AstraZeneca (AZN) reasserted mid- to high-single-digit revenue growth and low-double-digit core EPS growth for 2026. UBS doubts a guidance raise and questions the $80B 2030 revenue goal.
- FDA Extends Etcamah Review: FDA extended review of AstraZeneca’s Etcamah application after updated trial data showed reduced progression/death vs standard care; ongoing study to assess overall survival.
- Destiny-Breast09: Enhertu Benefit: DESTINY-Breast09: Enhertu+pertuzumab cut progression/death risk 44% vs THP (HR 0.56); median PFS 40.7 vs 26.9 months; ORR 85.1%; ILD/pneumonitis 12.1% (two grade 5).
- AZN Q2 Earnings Timing: AstraZeneca (AZN) will report Q2 earnings at 2:00 AM; estimated EPS 2.49. Traders note release timing and EPS ahead of the Q2 report.
- Royalty Pharma Backs AZN Cliramitug: Royalty Pharma bought part of Neurimmune’s royalty on AstraZeneca’s cliramitug for up to $425M: $125M upfront, $125M in Q1 2027, $175M tied to clinical/regulatory milestones; 3–4% global royalty.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.